Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Prolastin for severe COVID-19 ARDS
2020-001391-15Phase 2Completed
- Sponsor
- RCSI University of Medicine and Health Sciences
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alpha-1-proteinase inhibitor in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (3 arms), sponsored by RCSI University of Medicine and Health Sciences. Primary endpoint: Primary effectiveness outcome. Started Mar 2020; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001391-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001391-15.